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Thrombotic thrombocytopenic purpura (TTP) is a life-threatening systemic illness of abrupt onset and unknown cause. Proteolysis
of the blood-clotting protein von Willebrand factor (VWF) observed in normal plasma is decreased in TTP patients. However, the
identity of the responsible protease and its role in the pathophysiology of TTP remain unknown. We performed genome-wide
linkage analysis in four pedigrees of humans with congenital TTP and mapped the responsible genetic locus to chromosome 9q34.
A predicted gene in the identifed interval corresponds to a segment of a much larger transcript, identifying a new member of the
ADAMTS family of zinc metalloproteinase genes (ADAMTS13). Analysis of patients' genomic DNA identi®ed 12 mutations in the
ADAMTS13 gene, accounting for 14 of the 15 disease alleles studied. We show that de®ciency of ADAMTS13 is the molecular
mechanism responsible for TTP, and suggest that physiologic proteolysis of VWF and/or other ADAMTS13 substrates is required for
normal vascular homeostasis.
TTP is characterized by intravascular destruction of erythrocytes
and blood platelets resulting in anaemia and thrombocytopenia.
Diffuse platelet-rich microthrombi are observed in small blood
vessels of multiple organs, with the major complications including
renal failure and neurologic dysfunction. In the related disorder,
haemolytic uraemic syndrome (HUS), neurologic symptoms are
less evident and renal failure is more prominent. HUS is most
frequently observed in young children, usually following infection
with a speci®c Shiga-toxin-producing strain of Escherichia coli.
Although TTP-like disorders have also been associated with various
medications, bone marrow transplantation, pregnancy, human
immunode®ciency virus (HIV) infection, and autoimmune
disease, most cases appear sporadically, without an obvious
precipitating event. A subset of patients from these sporadic cases
experience a chronic relapsing course. Rare familial cases of TTP
have also been reported, generally associated with neonatal onset
and frequent relapses (OMIM (http://www.ncbi.nlm.nih.gov/Omim)
(accession numbers 274150 and 276850)1,2.
Before the development of modern treatment protocols consist-
ing of fresh-frozen plasma infusion with or without plasma
exchange, fatality during an acute episode of TTP was .90% (refs
2 and 3). Although treatment outcome has improved signi®cantly,
the molecular pathogenesis of TTP is still unknown and the speci®c
plasma factor(s) responsible for the acute onset of this disease, or
recovery after treatment, remains to be identi®ed. Unusually
large multimeric forms of the platelet-adhesive blood-coagulation
protein VWF have been observed in the plasma of TTP patients and
are proposed to have a pathogenic role in the formation of the
microvascular VWF- and platelet-rich thrombi characteristic of this
disorder4. Consistent with this hypothesis, a proteolytic activity that
degrades large VWF multimers to smaller sizes5,6 has been shown to
be decreased in the plasma of TTP patients, either on the basis of a
constitutional de®ciency in congenital cases or the presence of an
autoantibody inhibitor in most sporadic adult-onset cases7±10.
These ®ndings suggest that TTP may be triggered by accumulation
of large, highly adhesive VWF multimers in the absence of physio-
logic processing by this VWF-cleaving protease. However, other
studies have implicated platelet-aggregating proteins11,12 or
endothelial injury13 as the underlying mechanism, and enhanced
rather than decreased VWF proteolysis has been reported in some
patients14. Although the VWF-cleaving protease has been partially
puri®ed5,6, it seems to be present at relatively low levels in plasma
and its identi®cation at the sequence level has remained elusive.
VWF-cleaving protease activity is a semidominant trait
To further explore the molecular pathogenesis of TTP, we used a
genetic approach to study the four pedigrees shown in Fig. 1.
Activity of VWF-cleaving protease was measured in the plasma of
the seven affected individuals, and was 2±7% of normal (0.02±
0.07 U ml-1); none of the patients tested positive for inhibitors of the
protease. Plasma levels of the protease in the parents of the affected
individuals were 0.51±0.68 U ml-1, consistent with a heterozygous
articles
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carrier state. Similarly, levels for at-risk siblings of the patients and
parents fell into a bimodal distribution, with one peak consistent
with carriers and the other indistinguishable from the normal
distribution (Fig. 2). These results demonstrate that the protease
activity assay used here reliably distinguishes between normal and
carrier individuals in these families. This observation suggested that
the plasma level of VWF-cleaving protease could be used as a
phenotypic trait for linkage analysis to map the corresponding
locus, providing considerably greater genetic power than would be
available from analysis of the clinical phenotype alone.
Gene for familial TTP maps to chromosome 9q34
A genome-wide linkage scan was performed with 382 polymorphic
microsatellite markers to analyse DNA from affected individuals
and other informative family members (Fig. 1). Two-point linkage
analysis with a recessive model gave a maximum lod (log likelihood
ratio) score of 2.36 at v = 0.0 for marker D9S164 on chromosome
9q34. A lod score of 5.63 at v = 0.0 was obtained for the same marker
with a codominant model. There was still substantial evidence of
linkage to D9S164 when a codominant model with 95% penetrance
was used (lod score of 4.12 with v = 0.0 at D9S164). Multipoint
analysis for D9S164 and four ¯anking markers yielded a maxi-
mum lod score of 7.37 at marker D9S164. Genotypes for seven
additional markers in this region15,16 allowed the gene to be placed in
the ,7-centimorgan (cM) interval between markers D9S1863 and
D9S1818 (Figs 1 and 3a). Analysis of new polymorphic markers (see
Supplementary Information Table 3) designed using simple
sequence-repeat data available from the Human Genome Project
working draft (http://genome.ucsc.edu)17 further narrowed the
candidate interval to an ,2.3-megabase (Mb) genomic segment
between markers GL2-1 and D9S1818. In all but one case, carrier
status as determined by haplotype analysis was consistent with the
phenotypic designation according to plasma protease level. The
exception, individual II2 in pedigree A, shares the affected haplo-
type of her brother (II4), but has a protease level of 0.8 U ml-1,
which is borderline between the normal and carrier ranges.
Gene for familial TTP encodes an ADAMTS metalloproteinase
Analysis of the candidate interval using public genome databases
(http://genome.ucsc.edu, http://www.ncbi.nlm.nih.gov)17 identi-
®ed ,20 known or predicted genes (Fig. 3a). Initial attention
focused on genes likely to encode a protease or protease cofactor.
Ficolin 2 (FCN2) mapped to distal chromosome 9 but could not be
identi®ed in available BAC sequence from the candidate interval.
However, in light of previous reports suggesting a protease-
associated function for some ®colin family members18, and the
possibility that FCN2 might lie in one of the three large genomic
sequence gaps shown in Fig. 3a, the coding exons and intron±exon
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Figure 1 Pedigrees used for linkage analysis. VWF-cleaving protease levels (in units per
millilitre) are shown beneath the symbol for each individual. Circles indicate females
and squares indicate males. Affected individuals are indicated by solid symbols and
carriers by symbols with dots. Individual AII-2 was classi®ed as phenotype unknown
(hatched symbol) on the basis of an intermediate protease level (0.8). Seventeen markers
(13 from the Genethon15 and Marsh®eld16 comprehensive genetic maps and four
designed from sequence-repeat information available at the Human Genome Project
working draft17 (see Supplementary Information Table 3)) were used for haplotype
analysis. Only selected markers are shown. Chromosomes carrying affected alleles are
blue and normal chromosomes are yellow. Areas where recombination cannot be
de®nitively assigned are orange. Only recombination events between affected and
unaffected chromosomes are shown. Inferred genotypes are indicated in parentheses,
and genotypes of unknown phase in square brackets. Recombination events in individuals
AIII-3 and BII-6 place the responsible gene below marker GL2-1 and a recombination
event in individual AIII-2 places the gene above marker D9S1818.
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boundaries of this gene were ampli®ed by polymerase chain reac-
tion (PCR) from patients' DNA and subjected to sequence analysis.
No candidate mutations were identi®ed. Two putative genes in the
candidate interval, KIAA0605, an uncharacterized expressed
sequence tag (EST) from a brain complementary DNA library19,
and the predicted open reading frame C9ORF8, exhibited homology
to the ADAMTS family of metalloproteinases, but seemed to lack
the conserved protease catalytic domain. Partial DNA sequence
analysis of exons and ¯anking intron sequences failed to identify any
mutations in KIAA0605. However, the identi®cation of several
candidate missense mutations in the predicted exons of C9ORF8
led to further, more detailed analysis of this candidate gene.
Through a combination of cDNA cloning, PCR with reverse
transcription (RT-PCR), rapid ampli®cation of cDNA ends
(RACE) and genomic sequence analysis, the full-length
ADAMTS13 cDNA sequence (GenBank accession number
AF414401) and corresponding genomic structure were deduced
(Fig. 3b) and found to encode a complete, potentially catalytically
active ADAMTS protease.
Members of the ADAM (a disintegrin and metalloproteinase)
family are membrane-anchored proteases with diverse functions.
Known members include fertilins a and b, implicated in sperm±egg
fusion, and the `sheddases', such as TACE (TNF-a convertase),
which mediate the shedding of cell-surface proteins20. Members of
the ADAMTS family are distinguished from ADAMs by the presence
of one or more thrombospondin-1-like (TSP1) domain(s) at the
carboxy terminus, which are thought to mediate interactions with
components of the extracellular matrix21±24. In addition, ADAMTS
proteins lack the EGF repeat, transmembrane domain and cyto-
plasmic tail typically observed in ADAM metalloproteinases. Muta-
tions in ADAMTS2 (procollagen N-proteinase), the only family
member previously associated with a human genetic disease, result
in the connective tissue disorder, Ehlers-Danlos syndrome type VII
(ref. 25). Although ADAMTS1 mutations have not been identi®ed
in humans, genetically de®cient mice exhibit growth retardation,
adipose tissue abnormalities, and ®brotic changes throughout the
genitourinary system, suggesting a critical importance for
ADAMTS1 in organogenesis and tissue remodelling26. ADAMTS4
and ADAMTS5/11 (aggrecanases) cleave the core protein of the
cartilage proteoglycan, aggrecan, and may be important in in¯am-
matory joint disease27. Procollagen II has recently been identi®ed as
the substrate for ADAMTS3 (ref. 28). The function and protein
substrates for the remaining ADAMTS family members are
unknown.
The ADAMTS13 gene spans 29 exons encompassing ,37 kb in
the human genome and encodes a protein with 1,427 amino acids
(Fig. 3b). Analysis of RT-PCR and cloned cDNA sequences provided
evidence for alternative splicing of exon 17 (GenBank accession
number AF414400), resulting in a frameshift that predicts a trun-
cated 842-amino-acid form of the protein lacking the six C-terminal
TSP1 repeats. Comparative analysis with draft mouse genomic
sequences demonstrates a high degree of conservation throughout
the coding exons and identi®es an additional potential exon located
between the current exons 22 and 23, which may indicate another
splice isoform. These ®ndings suggest the potential for differentially
regulated alternative isoforms of ADAMTS13 with diverse biological
functions in addition to the putative proteolytic processing of VWF.
Alternative splicing has been observed for two other ADAMTS genes,
ADAMTS2 (ref. 25) and ADAMTS9 (ref. 23), resulting in similar
variation in the number of C-terminal TSP1 repeats.
The domain structure of ADAMTS13 is depicted at the bottom of
Fig. 3b. A predicted signal peptide is followed by a short propeptide
domain ending in a potential propeptide convertase cleavage site at
amino acids 71±74 (RQRR), suggesting that proteolytic processing,
either in the trans Golgi or at the cell surface, is required for
activation. The protease domain that follows contains a perfect
match for the HEXGHXXGXXHD (where X is any amino acid)
consensus sequence of the extended catalytic site shared between
snake venom metalloproteinases and ADAM family members20,21,29.
The catalytic domain is followed by TSP1 and spacer domains
characteristic of the ADAMTS family. An RGD sequence, present in
only one other mature ADAMTS protein (ADAMTS2), is located
immediately C terminal to the ®rst TSP1 domain of ADAMTS13,
suggesting a possible integrin interaction. The C terminus contains
six additional TSP1 repeats, followed by a segment with homology
to the CUB domain identi®ed in a number of developmentally
regulated proteins30. The previously reported inhibitor pro®le and
metal cation dependence of the VWF-cleaving protease5,6,31 are
consistent with its identity as an ADAMTS. The predicted, non-
glycosylated relative molecular mass of ADAMTS13 is 154,000 (Mr
154K), consistent with a previously estimated Mr of 200K for
partially puri®ed VWF-cleaving protease5, although considerably
smaller than the 300K Mr reported by others
6.
Northern blot analysis detected an ADAMTS13 messenger RNA
of ,4.7-kb speci®cally in the liver, with a truncated (,2.3 kb)
mRNA faintly visible in the placenta (Fig. 4a). These data suggest
that plasma VWF-cleaving protease may be derived primarily from
ADAMTS13 expression in the liver. The strong RT-PCR signal seen
in the ovary, and variable expression in other tissues (Fig. 4b), may
point to other potential functions for this protein. The absence of
detectable transcripts in other highly vascular tissues such as the
lung and heart may indicate that the vascular endothelium is not a
primary site of ADAMTS13 expression.
Mutations in ADAMTS13 cause familial TTP
Analysis of DNA sequences identi®ed mutations within the
ADAMTS13 gene in all four of the pedigrees depicted in Fig. 1, as
well as in three additional TTP patients not included in the original
articles
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Figure 2 Plasma VWF-cleaving protease levels. a, Levels for all individuals shown in
Fig. 1, as well as additional members of family A. b, Levels for 61 normal control
individuals. Affected individuals are indicated by red circles, obligate carriers (parents of
affected individuals) by orange triangles, other individuals at risk for inheriting an affected
allele by green diamonds, and additional members of family A not at risk by open
hexagons. Normal controls are shown as blue triangles. Levels for at-risk individuals
(green diamonds in a) fall into a bimodal distribution, with one peak ranging from 0.45 to
0.68 U ml-1, consistent with carriers, and the other from 0.90 to 1.17 U ml-1,
indistinguishable from the normal distribution shown in b. Not shown here, probands E, F
and G had VWF-cleaving protease activities of 0.05, 0.04 and 0.09 U ml-1, respectively,
and no detectable inhibitor. The parents of proband E had VWF-cleaving protease levels of
0.49 and 0.63 U ml-1 and the parents of proband G had levels of 0.53 and 0.68 U ml-1.
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genome scan (families E±G, Table 1). The 12 mutations identi®ed
account for all but one of the 15 disease alleles expected in this set of
patients (Table 1 and Fig. 5, and see Supplementary Information
Figs 6 and 7). No recurrent mutation was observed, except in family
A (Fig. 5). All three affected individuals in this family are homo-
zygous for the same mutation carried on the same extended
haplotype (data not shown), suggesting recent common ancestry.
Although there is no known consanguinity, the parents of affected
individuals AIII-2, AIII-3 and AIII-8 are all from the same small
village where the families have lived for several generations.
Two of the 12 identi®ed mutations result in frameshifts (a 26-base
pair (bp) deletion in exon 19 (Fig. 5) and a single T insertion in
exon 27). A single splice mutation was identi®ed in one family
(1584 + 5G ! A, family G). This substitution markedly reduces or
eliminates utilization of the normal intron 13 splice donor and
activates a cryptic donor splice site at +70, resulting in a 23-codon
insertion (see Supplementary Information Fig. 6). The remaining
nine mutations all result in nonconservative amino-acid substitu-
tions (Table 1) and all occur at positions that are perfectly conserved
between the human and murine genes. H96D in the catalytic
domain and R398H in the ®rst TSP1 domain both alter residues
that are almost perfectly conserved among all known ADAMTS
family members. All 12 of the ADAMTS13 gene mutations
described above were excluded as common sequence polymorph-
isms by screening a large panel of unaffected chromosomes. Many
single-nucleotide polymorphisms (SNPs) were also identi®ed,
although only 7 of 25 result in amino-acid substitutions (see
Supplementary Information Table 2).
The spectrum of ADAMTS13 mutations observed here is notable
for the relative paucity of obvious null alleles. In addition, the single
splice mutation and two frameshift mutations all occur in trans with
a missense mutation on the other allele. These data suggest that
complete de®ciency of ADAMTS13 may be lethal, consistent with
the low levels of residual VWF-cleaving protease activity observed in
all ten de®cient patients studied here (0.02±0.09 U ml-1).
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Figure 3 Identi®cation of the ADAMTS13 gene. a, Physical map of chromosome 9 in the
interval surrounding marker D9S164. The 2.3-Mb nonrecombinant interval identi®ed in
Fig. 1 is shown in red. Sequence gaps in the public genomic draft assembly are denoted
by blue rectangles. Transcripts localized to this interval are depicted by alternating
black and grey bars. The predicted gene C9ORF8 is indicated with a red asterisk and is
located ,32 kb telomeric to D9S164, on the basis of the current draft human genome
sequence17. The reference bar represents 1 Mb. b, Intron±exon and domain structures of
ADAMTS13. The coding region is illustrated in grey and 59 and 39 untranslated regions in
green. Intron sizes are not drawn to scale. Exon 1 of C9ORF8 overlaps with a cluster of
EST sequences (UniGene cluster Hs.149184), initially interpreted as predicting a large
59 untranslated region. A segment of putative C9ORF8 coding sequence was used to
identify two partial cDNA clones from human fetal liver, which were extended in both the
59 and 39 directions by RT-PCR and RACE. The assembled cDNA sequence corrected an
error in the predicted boundaries of C9ORF8 exon 2, resulting in a continuous open
reading frame including two exons upstream of the 59 EST cluster, three new exons within
the predicted intron 10 of C9ORF8 and six additional downstream exons encompassing a
second hypothetical gene in this region, DKFZp434C2322 (Unigene cluster Hs.131433).
Analysis of RT-PCR and cDNA sequences identi®ed an alternatively spliced variant of exon
17 using both alternate donor and acceptor splice sites, as indicated. Mutations are
depicted underneath the corresponding exons, with green triangles representing
missense mutations and red squares representing frameshift and splice mutations.
Scale bar, 200 nucleotides. The predicted domain structure of ADAMTS13 is shown
at the bottom. The predicted signal peptide (predicted using SignalP version 1.1
(http://www.cbs.dtu.dk/services/SignalP)) is indicated in orange, the short propeptide in
blue, the metalloproteinase domain in yellow, the disintegrin domain in green, and TSP1
domains as light blue ovals. The locations of the zinc-binding catalytic consensus within
the metalloproteinase domain and the cysteine-rich region within the spacer domain are
indicated. The CUB domain (dark blue) has not been identi®ed in other ADAMTS family
members. Scale bar, 50 amino acids.
Table 1 ADAMTS13 mutations in thrombotic thrombocytopenic purpura
Exon Family Nucleotide Amino acid
.............................................................................................................................................................................
3 B 286C ! G H96D
3 E 304C ! T R102C
6 E 587C ! T T196I
10 D 1193G ! A R398H
13 C 1582A ! G R528G
13 G 1584+5G ! A Splice
17 A 2074C ! T R692C
19 F 2376±2401D Frameshift
22 B 2851T ! G C951G
24 D 3070T ! G C1024G
26 F 3638G ! A C1213Y
27 C 3769±3770insT Frameshift
.............................................................................................................................................................................
Genomic DNA from patients was used to amplify exons and intron±exon boundaries of ADAMTS13.
For mutations in families A±D, candidate mutations were con®rmed in both parents. All mutations
were con®rmed as absent from ,180 control normal chromosomes by PCR, allele-speci®c
oligonucleotide hybridization or restriction digest.
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Discussion
The ®ndings reported here identify genetic de®ciency of
ADAMTS13 as the underlying molecular mechanism responsible
for most or all cases of familial TTP. This disorder seems to be
identical to the congenital microangiopathic haemolytic anaemia
also referred to as Schulman-Upshaw syndrome32 (OMIM number
276850). Although symptomatic anaemia and thrombocytopenia
are usually present at birth, two of the patients studied here
(proband G and BII-2) did not experience their ®rst episodes of
TTP until the ages of 4 and 8 years, respectively, despite clinical
disease as neonates in siblings of both individuals. This highly
variable age of onset, even within the same family, suggests a major
contribution of other genetic and/or environmental modifying
factors that remain to be identi®ed. Previous studies have demon-
strated antibody inhibitors directed against the VWF-cleaving
protease in most adult TTP patients, suggesting an autoimmune
aetiology7,10. However, the late onset of this disorder observed in two
of the ten patients in our series raises the possibility that a subset of
apparently sporadic adult-onset TTP may be due to unrecognized
recessive inheritance of ADAMTS13 mutations.
The nearly perfect correlation of plasma VWF-cleaving protease
activity with TTP carrier status that we observed was critical to the
success of the genetic linkage analysis reported here. Although these
data indicate that the plasma levels of this protease activity are very
tightly regulated, to date no clinical phenotype has been detected in
previously reported familial TTP carriers, or in any of the
ADAMTS13-mutation heterozygotes identi®ed here. However, the
presence of a subtle phenotype in these individuals, such as
increased susceptibility to thrombosis or to one or more of the
`acquired' forms of TTP, cannot be excluded.
Our data provide the ®rst direct evidence of an aetiologic role for
VWF-cleaving protease activity in the pathogenesis of TTP and
identify the enzyme likely to be responsible for this activity:
metalloproteinase ADAMTS13. Physiologic cleavage of VWF at
the Tyr 842±Met 843 peptide bond produces the characteristic
176K proteolytic fragment observed in normal plasma5,6,33 and
increased susceptibility to this proteolytic cleavage seems to be
responsible for the loss of large VWF multimers central to the
pathophysiology of type 2A von Willebrand disease (VWD)31,34.
Taken together with previous work from our group and
others4±7,10, our data strongly suggest that ADAMTS13 is the
VWF-cleaving protease itself. However, we cannot exclude the
possibility that ADAMTS13 acts on VWF indirectly, perhaps by
activating another protease. In either case, our data are consistent
with the hypothesis that accumulation of large, hyperactive VWF
multimers in the absence of normal proteolytic processing triggers
pathologic platelet aggregation and is the direct mechanism respon-
sible for TTP. Alternatively, decreased VWF proteolysis could solely
be a marker for the loss of ADAMTS13 activity. ADAMTS13
may also have important biological functions elsewhere in the
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Figure 4 Northern and RT-PCR analysis of ADAMTS13. a, A northern blot of RNA from
multiple human tissues was hybridized with a probe spanning exons 11±13 and part of
exon 14. An ,4.7-kb message can be seen speci®cally in liver and a truncated ,2.3-kb
message is faintly visible in placenta. b, A panel of cDNAs derived from human tissues was
screened by PCR for the presence of exons 10±14. Strong signals were seen in liver and
ovary, with weak expression also evident in kidney, pancreas, spleen, thymus, prostate,
testis, small (sm.) intestine and peripheral blood leukocytes (PBLs). No expression was
















Figure 5 ADAMTS13 mutations in TTP patients. a, Sequence chromatograms of PCR-
ampli®ed exon 17 from a control individual and an affected individual from family A. The
arrow indicates the position of the 2074C ! T (R692C) mutation. The single mutant T
peak in the patient sequence chromatogram indicates homozygosity for this mutation.
b, Sequence chromatograms of PCR-ampli®ed exon 26 identify the heterozygous
3638G ! A (C1213Y) mutation (arrowed), accounting for one of the mutant alleles in
family F. c, Analysis of the second mutant allele in family F. Sequence chromatograms of
PCR-ampli®ed exon 19 from a normal control (top panel) and the cloned 2376±2401D
deletion allele (third panel) are shown. Sequence analysis of total PCR product from the
patient (middle panel) demonstrates the superimposed normal and deletion allele
sequences, indicating that the patient is heterozygous for this mutation. The underline in
the control sequence indicates the 26-bp deletion with the arrows in the other traces
indicating the start of the deletion.
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coagulation system or in the blood vessel wall, with loss of one or
more of these activities providing the direct link to the pathogenesis
of TTP. Future studies of ADAMTS13 function, both in vivo and
in vitro, should answer these questions and provide insight into
the complex biological processes regulating haemostasis and the
maintenance of vascular integrity. Finally, the identi®cation of
ADAMTS13 de®ciency as the cause of TTP also has major implica-
tions for the treatment of this important human disease, including
the potential for production of recombinant ADAMTS13 as a
safer and more effective replacement for current plasma-exchange
therapy.
Note added in proof: Fujikawa et al.35 and Gerritsen et al.36 have
reported puri®cation and sequence analysis of the amino-terminal
amino acids of human VWF-cleaving protease. These results con-
®rm the identity of ADAMTS13 as the VWF-cleaving protease and
its predicted processing by propeptide convertase cleavage. M
Methods
Subjects
Patients included in this study were referred for evaluation of thrombocytopenia,
haemolytic anaemia and schistocytes on blood smear. Probands for the four families
(A±D) used in the linkage analysis all had a chronic relapsing course, responded to plasma
infusion, and had the disorder as neonates or had a family member with such a disorder as
a neonate. All three probands for kindreds E±G also had microangiopathic haemolysis
and/or thrombocytopenia noted soon after birth or in the early neonatal period (in the
patient or an affected sibling), along with clinical response to plasma infusion.
Plasma samples were obtained from sodium citrate anticoagulated blood by centrifu-
gation and saved at -70 8C as previously described7. Mononuclear cells were obtained from
heparin anticoagulated blood by centrifugation on Ficoll-Hypaque, washed and trans-
formed with Epstein-Barr virus. Informed consent was obtained from all individuals
before sample collection (study protocol approved by the institutional review board).
Multimer analysis and VWF-cleaving protease activity
Analysis of VWF multimers was performed as previously described7. Ultra large VWF
multimers were detected in the plasma of all TTP patients studied, with normal patterns
observed in all other family members. For the measurement of VWF-cleaving protease
activity, VWF treated with guanidine hydrochloride was used as the substrate. Protease
activity was represented by the optical density of the dimer of the 176K fragment generated
from the VWF substrate7 and was expressed in units per millilitre, with the activity
measured in pooled normal control plasma de®ned as 1 U ml-1. Protease activity is
reported as the mean of two measurements for the parents of families E and G. All other
samples were measured on at least three occasions, with the mean value reported. Assays
for inhibitors of VWF-cleaving protease were performed as described37.
Linkage analysis
A genome-wide linkage screen was performed with 382 polymorphic microsatellite
markers spaced an average of 10 cM (panels 1±27 of the ABI Prism Linkage Mapping Set-
MD10 (Applied Biosystems)). We ampli®ed 20 ng of genomic DNA with AmpliTaq Gold
DNA polymerase (Applied Biosystems). PCR products were run on an ABI Prism 3700
DNA Analyzer and analysed with Genescan version 3.5NT and Genotyper version 3.6NT.
Inspection of the pedigrees indicated an autosomal recessive mode of inheritance for TTP
in this set of families. The frequency of the disease gene was assumed to be 1 per 10,000
chromosomes in the population. Population frequencies of the marker alleles were
estimated from the genotyped individuals. Two-point lod scores were calculated with the
program MLINK as implemented in the FASTLINK package version 3.0 (ref. 38), with an
autosomal recessive model. A second series of analyses was performed with a codominant
model to re¯ect the lowered enzyme levels of individuals who were assumed to be carriers of
the disease gene. For the latter analysis, individuals were classi®ed as affected (those with
clinical diagnoses), carriers (those with protease levels in the range of 0.45±0.68 U ml-1) and
unaffected (those with protease levels in the range of 0.9±1.17 U ml-1). One individual
(AII-2), whose protease level was intermediate between the carrier and unaffected ranges,
was classi®ed as phenotype unknown. Penetrance was set at 100% for the recessive model
and codominant models. Consistency of the linkage evidence was evaluated by recomputing
the lod score with 95% penetrance for the codominant model. Multipoint analyses were
performed with the program VITESSE39, using the same two disease models and the ®ve
markers at or ¯anking the maximum two-point lod score (centromere-D9S1682-D9S290-
D9S164-D9S1826-D9S158-telomere). Order and distances between markers were deter-
mined with the ABI Prism Linkage Mapping Set-MD10 map information. To ensure the
multipoint analyses were computationally feasible, the number of founders in pedigree A
was reduced and less-informative individuals (II-1, -2, -3 and -13, and III-8 and -9) were
pruned from the pedigree.
Sequence analysis
All exons and intron±exon boundaries of the predicted ADAMTS13 gene were ampli®ed
from patients' genomic DNA, with the exception of exon 7, which could not be ampli®ed
with multiple primer sets. Intron primers were selected with the Primer3 software package
(S. Rozen and H. J. Skaletsky, 1998; code available at http://www-genome.wi.mit.edu/
genome_software/other/primer3.html) to allow for analysis of exon sequence as well as
¯anking donor and acceptor splice sites. (See Supplementary Information Table 4 for
primer sequences.) We used 100 ng of genomic DNA in a PCR reaction using either
Platinum Taq DNA polymerase (Invitrogen), the Expand Long Template DNA polymerase
mix (Roche) or the Advantage 2 DNA polymerase mix (Clontech). PCR products were
either puri®ed directly from the PCR reaction using the QIAquick PCR puri®cation kit
(Qiagen) or gel puri®ed from low-melting agarose (Invitrogen) with the Wizard PCR
Preps puri®cation kit (Promega). Total cellular RNA from lymphoblast cell lines was
prepared with Trizol (Invitrogen) and RT-PCR performed with the One-Step RT-PCR
kit (Invitrogen), according to the manufacturer's instructions. Sequencing reactions
were performed by the University of Michigan DNA Sequencing Core. Selected PCR
products were subcloned into a pCR-TOPO plasmid (Invitrogen) for further sequence
analysis.
Allele-speci®c oligonucleotide hybridization
Individual exons were ampli®ed from 92 unrelated control individuals. For allele-speci®c
oligonucleotide hybridization, PCR products were spotted onto nitrocellulose membranes
by a dot-blot apparatus (Invitrogen). Fifteen-base oligonucleotides corresponding
to wild-type or mutant alleles were end-labelled with g-32P-ATP by T4 polynucleotide
kinase (New England Biolabs). Hybridization was performed in ExpressHyb solution
(Clontech) at 37 8C. Blots were washed in 5 ´ SSPE, 0.1% SDS at a temperature determined
empirically for each oligonucleotide. Restriction-digested PCR products were analysed on
a 3% NuSieve GTG agarose (BioWhittaker), 1% agarose (Invitrogen) gel.
RT-PCR and northern blot analysis
RT-PCR on patient RNA and PCR on cDNA obtained from a Multiple Tissue cDNA panel
(Clontech) were performed using primers 59-CAGTGCAACAACCCCAGAC-39 and
59-GGCACCTGTCCCATACCTG-39, which amplify cDNA nucleotides 1,228±1,636
(numbered from the initiator ATG as +1). A FirstChoice Human Northern Blot (Ambion)
was screened with a probe generated by random priming using the Rediprime II kit
(Amersham) of a PCR product ampli®ed from a human MOLT4 T-cell cDNA library
(generated as previously described40) with the above primers. Hybridization was per-
formed in ExpressHyb solution (Clontech) according to the manufacturer's speci®cations.
The ®nal wash step was performed in 0.1´ SSC, 0.1% SDS at 50 8C.
Isolation of cDNA
A human fetal liver cDNA library in lgt10 (Clontech) was screened with the northern
probe described above. Two overlapping cDNA clones were obtained, spanning exons
5±14 and 8±20 of the predicted ADAMTS13 cDNA sequence. Phage DNA was puri®ed
with a Nucleobond lambda midi kit (Clontech), digested with EcoRI (New England
Biolabs) and subcloned into pBSII-SK+ (Stratagene). We performed 59 RACE on
FirstChoice RACE-Ready human liver cDNA (Ambion). Additional 59 RACE was
performed with the 59/39 RACE kit (Roche) on human liver polyA+ RNA (Ambion).
Marathon-Ready human liver cDNA (Clontech) was used for 39 RACE and for an internal
RT-PCR, the latter to amplify a product spanning cDNA nucleotides 1,552±2,627. RACE
and RT-PCR products were cloned into a pCR-TOPO vector (Invitrogen) and individual
clones were subjected to sequence analysis. Nucleotides bridging 59 RACE and cDNA
clones (cDNA nucleotides 456±534) were obtained from the C9ORF8 EST cluster
(UniGene cluster Hs.149184). Exon±intron boundaries and sequence accuracy were
veri®ed against available draft human sequence at http://www.ncbi.nlm.nih.gov17.
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